MatriSys Bio is developing a novel class of biopharmaceuticals that utilize beneficial bacteria derived from healthy human skin to treat chronic inflammatory skin conditions. This approach aims to restore skin homeostasis for millions of patients suffering from dermatological diseases such as atopic dermatitis and acne, reducing reliance on steroids and antibiotics.
Funding
$14.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Chronic inflammatory skin conditions like atopic dermatitis, acne, and rosacea affect millions, significantly impacting quality of life. Current treatments often rely on steroids, immunosuppressants, and antibiotics, which can have undesirable side effects and may not provide long-term solutions. There is a significant unmet need for therapies that restore skin homeostasis without these drawbacks.
Solution
MatriSys Bio is developing a novel class of biopharmaceuticals based on beneficial bacteria sourced from healthy human skin. Their approach involves topical application of these bacteria to restore skin homeostasis, which is often disrupted in chronic inflammatory skin diseases. By re-establishing a healthy skin microbiome, MatriSys aims to provide a more natural and sustainable treatment option, potentially reducing the reliance on traditional medications with harsh side effects. This technology platform identifies and cultivates specific bacterial strains with therapeutic potential for various dermatological conditions.
Target Audience
The primary target audience includes individuals suffering from chronic inflammatory skin conditions such as atopic dermatitis, acne, and rosacea, as well as dermatologists seeking alternative treatment options for their patients.
Features
- Identification and isolation of beneficial bacteria from healthy human skin
- Topical formulations containing live bacterial strains for direct application to affected areas
- Targeted restoration of skin microbiome balance
- Potential to reduce or replace the need for steroids, immunosuppressants, and antibiotics
- Pipeline of products targeting various chronic inflammatory skin conditions, including atopic dermatitis, acne, and rosacea